Thermo Fisher Scientific
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.
Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Stock Symbol: TMO
1632 articles about Thermo Fisher Scientific
-
Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
12/6/2022
Thermo Fisher Scientific today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.
-
Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
11/21/2022
Thermo Fisher Scientific Inc. will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).
-
Thermo Fisher Scientific Introduces All-in-One AAV Production System for Scalable Gene Therapy Workflows and Commercial Applications
11/16/2022
Gibco CTS AAV-MAX Helper-Free AAV Production System supports seamless transition from gene therapy research to manufacturing.
-
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - November 15, 2022
11/15/2022
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes.
-
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes - November 15, 2022
11/15/2022
Thermo Fisher Scientific Inc. announced that on November 14, 2022 it priced an offering of $1.2 billion aggregate principal amount of the following notes: $600 million aggregate principal amount of its 4.800% senior notes due 2027, at the issue price of 99.960% of their principal amount, and $600 million aggregate principal amount of its 4.950% senior notes due 2032, at the issue price of 99.797% of their principal amount.
-
Thermo Fisher Scientific Declares Quarterly Dividend - November 10, 2022
11/10/2022
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders of record as of December 15, 2022.
-
Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases
11/10/2022
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions.
-
Thermo Fisher Scientific and Society for Science Launch Junior Innovators Challenge to Inspire More Than 65,000 Future STEM Leaders Nationwide
11/3/2022
Thermo Fisher Scientific Inc., the world leader in serving science, and Society for Science, announced the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math competition.
-
ChromaCode Showcases HDPCR Oncology Data on QuantStudio Absolute Q dPCR System at the AMP 2022 Annual Meeting
11/1/2022
ChromaCode, Inc., which brings accessible and affordable insights to labs, patients and physicians through its innovative High Definition PCR (HDPCR™) multiplexing solution, announced today that it will present its HDPCR oncology data, studied in collaboration with Thermo Fisher Scientific, on the QuantStudio Absolute Q dPCR* System at the Association for Molecular Pathology (AMP) 2022 Annual Meeting and Expo.
-
Thermo Fisher Scientific to Acquire The Binding Site Group
10/31/2022
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”).
-
Thermo Fisher Scientific Showcases Pharma Services Innovation and Expertise at CPHI Frankfurt 2022
10/31/2022
This week at CPHI Frankfurt, Thermo Fisher Scientific will showcase its expertise, innovations and capabilities to help pharmaceutical and emerging biotech companies accelerate time to market across a wide range of modalities and platforms, including cell and gene therapies, oral solids, steriles and biologics
-
Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy
10/31/2022
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment.
-
Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022
10/31/2022
Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology taking place at the Phoenix Convention Center from Nov.
-
Thermo Fisher Scientific to Expand Clinical Research Laboratory in Kentucky
10/27/2022
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced plans to invest $59 million to significantly expand its laboratory operations in Highland Heights, Kentucky, helping customers deliver life-changing medicines to patients.
-
Genoox partners with Thermo Fisher Scientific to automate cytogenetic research data interpretation and reporting with AI
10/27/2022
Thermo Fisher Scientific has upgraded its leading Applied Biosystems Chromosome Analysis Suite (ChAS) software through a collaboration with Genoox, a community-driven genomic data company.
-
Thermo Fisher Scientific Reports Third Quarter 2022 Results
10/26/2022
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended October 1, 2022.
-
Thermo Fisher Scientific demonstrates commitment to transplant patients and collaboration at ASHI 2022
10/24/2022
Thermo Fisher Scientific, the world leader in serving science, will demonstrate the benefits of collaborating to advance the science of transplantation and connecting breakthroughs to patients this week at the 48th Annual Meeting of the American Society for Histocompatibility & Immunogenetics Conference in Las Vegas.
-
Thermo Fisher Scientific Launches Closed and Automated Cell Isolation and Bead Removal Solution to Help Evolve Cell Therapy Manufacturing
10/17/2022
Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ DynaCellect™ Magnetic Separation System (DynaCellect) to help cell therapy developers easily move from process and clinical development to commercial manufacturing.
-
Thermo Fisher Scientific Prices Offering of Yen-Denominated Senior Notes
10/14/2022
Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has priced an offering of ¥109.5 billion aggregate principal amount of the following yen-denominated notes, each issued at par.
-
Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia
10/12/2022
$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development Thermo Fisher Scientific, the world leader in serving science, expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia.